501 related articles for article (PubMed ID: 33692146)
21. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
Mao Y; Xu X
Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
[TBL] [Abstract][Full Text] [Related]
22. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
23. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
24. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
25. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Chohan KL; Bansal R; Hathcock MA; Paludo J; Bennani NN; Johnston PB; Khurana A; Durani U; Wang Y; Ruff MW; Villasboas Bisneto JC; Ansell SM; Lin Y; Kenderian SS
Leuk Lymphoma; 2024 Mar; 65(3):389-393. PubMed ID: 38031734
[No Abstract] [Full Text] [Related]
26. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
27. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
28. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
Diorio C; Shraim R; Myers R; Behrens EM; Canna S; Bassiri H; Aplenc R; Burudpakdee C; Chen F; DiNofia AM; Gill S; Gonzalez V; Lambert MP; Leahy AB; Levine BL; Lindell RB; Maude SL; Melenhorst JJ; Newman H; Perazzelli J; Seif AE; Lacey SF; June CH; Barrett DM; Grupp SA; Teachey DT
Clin Cancer Res; 2022 Sep; 28(17):3804-3813. PubMed ID: 35705524
[TBL] [Abstract][Full Text] [Related]
30. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
31. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
32. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
33. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
34. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy
Chen Y; Li R; Shang S; Yang X; Li L; Wang W; Wang Y
Front Immunol; 2021; 12():623610. PubMed ID: 34093519
[TBL] [Abstract][Full Text] [Related]
35. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
Sun Z; Xie C; Liu H; Yuan X
Front Immunol; 2022; 13():778192. PubMed ID: 35154102
[TBL] [Abstract][Full Text] [Related]
36. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
[TBL] [Abstract][Full Text] [Related]
37. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
38. A major role for CD4
Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P
Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589
[TBL] [Abstract][Full Text] [Related]
39. Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist.
Pawar DS; Molinaro JR; Knight JM; Heinrich TW
Psychosomatics; 2019; 60(5):519-523. PubMed ID: 30717979
[No Abstract] [Full Text] [Related]
40. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
